» Articles » PMID: 1718063

Prevention of Graft-versus-host Disease Following Allogeneic Bone Marrow Transplantation in Rats Using FK506

Overview
Journal Transplantation
Specialty General Surgery
Date 1991 Oct 1
PMID 1718063
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

FK506 and cyclosporine were used for the prevention of acute graft-versus-host disease. Acute GVHD was induced in Lewis rats by total-body irradiation and subsequent reconstitution with allogeneic (ACI) bone marrow and spleen cells (BMTx). GVHD was assessed by both clinical and histologic parameters during the experiment duration of 60 days, and longer for selected animals. All untreated BM recipients died within 26 days from severe acute GVHD. GVHD was prevented with CsA during the period of immunosuppressive therapy, but it appeared within a few days afterward. FK506-treated BM recipients were also protected, but they had a markedly prolonged GVHD-free period after therapy was discontinued. Most such animals eventually developed GVHD but with notable exceptions. Maintenance therapy with doses of FK506 as low as 0.1 mg/kg every other day (1/20 of daily induction dose) was infallible insurance against delayed GVHD. The relevance of these findings to GVHD caused by lymphoid-containing solid organs such as the intestine was discussed.

Citing Articles

Xenogeneic humoral graft-Vs-host disease following hamster-to-Rat bone marrow transplantation.

Miki T, Lee Y, Tandin A, Subbotin V, Kuddus R, Rao A Transplant Proc. 2000; 32(5):1036-7.

PMID: 10936339 PMC: 2996871. DOI: 10.1016/s0041-1345(00)01105-2.


Cytokine profile in graft-versus-host disease after small bowel transplantation.

Galvao F, Murase N, Todo S, Zeevi A, Ye Q, Doughton C Transplant Proc. 1996; 28(5):2455.

PMID: 8907897 PMC: 2958701.


Effect of tacrolimus and splenectomy on engraftment and GVHD after bone marrow xenotransplantation in the reciprocal hamster to rat animal models.

Pan F, Tsugita M, Rao A, Wakizaka Y, Sun H, Park I Transplant Proc. 1996; 28(2):736-7.

PMID: 8623373 PMC: 2954625.


Treatment options--commentary.

Arceci R Br J Cancer Suppl. 1994; 23:S58-60.

PMID: 8075010 PMC: 2149716.


FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects.

Wallemacq P, Reding R Clin Chem. 1993; 39(11 Pt 1):2219-28.

PMID: 7693372 PMC: 2978067.


References
1.
Markus P, Cai X, Ming W, Demetris A, Fung J, Starzl T . FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. Surgery. 1991; 110(2):357-63; discussion 363-4. PMC: 2956606. View

2.
Murase N, Demetris A, Matsuzaki T, Yagihashi A, Todo S, Fung J . Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery. 1991; 110(1):87-98. PMC: 2975982. View

3.
Fung J, Todo S, Tzakis A, Alessiani M, Abu-Elmagd K, Jain A . Current status of FK 506 in liver transplantation. Transplant Proc. 1991; 23(3):1902-5. PMC: 2955871. View

4.
Iwaki Y, Starzl T, Yagihashi A, Taniwaki S, Abu-Elmagd K, Tzakis A . Replacement of donor lymphoid tissue in small-bowel transplants. Lancet. 1991; 337(8745):818-9. PMC: 2983478. DOI: 10.1016/0140-6736(91)92517-6. View

5.
Murase N, Kim D, Todo S, Cramer D, Fung J, Starzl T . Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation. 1990; 50(2):186-9. PMC: 2978534. DOI: 10.1097/00007890-199008000-00002. View